CLICK TO READ ENTIRE TRANSCRIPT
With the reach and impact of biopharma growing exponentially, experts in biotech and the evolving regulatory environment came together in November 2022 to discuss the critical next steps for the industry. As well as highlighting the enormous potential for breakthrough treatments for rare diseases, the panel’s subject matter experts discussed the ways the industry must continue to adapt its regulatory approaches if promising new therapies are to be brought to market swiftly and efficiently, without compromising patient safety.
This first Science Huddle session considered the necessary evolution of clinical trials, and new means of eliciting critical safety data, when available patient populations are small – and when successful outcomes may not be immediately tangible or measurable in traditional ways.
